IP Library Granted Patent US 7,090,981
Granted Patent B2
US 7,090,981 · App. 10/772,020 · Granted Aug 15, 2006

Chicken anaemia viruses of low pathogenicity

Assignee: Akzo Nobel N.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,090,981
App. No.
10/772,020
Granted
Aug 15, 2006
Kind
B2
Abstract

The present invention provides a new antigenic type of chicken anaemia viruses (CAV). The CAV according to this invention is isolatable from turkeys in the field and its virulence for chickens is significantly reduced. This property makes these viruses particularly suited for preparing a live vaccine for protecting poultry against disease conditions resulting from CAV infection.

Claims (9)

1. A method for the preparation of CAV, comprising the steps of:

a. inoculating a susceptible substrate with the CAV,

b. propagating the virus, and

c. harvesting CAV containing material, wherein the CAV is an isolated chicken anaemia virus (CAV), wherein the virus is neutralized by a reference sample comprising monoclonal antibody R2 secreted by a hybridoma cell line, having the identifying characteristics of a sample deposited at the ECACC under accession no. 00020304 and the virus is not a chicken anemia agent (CAA) virus attenuated by passaging wild type CAA virus in embryonated chicken eggs, wherein the virus induces lesions in chicken embryos, and wherein the antibody titre of the reference sample is at least 5 (log 2) per 50 μl when examined against 300–1000 TCID 5 per 50 μl of the CAV.

2. A method for the preparation of a vaccine for protecting poultry against disease conditions resulting from a CAV infection, comprising the step of combining the harvested CAV containing material prepared according to the method of claim 1 with a pharmaceutically acceptable carrier or diluent.

3. The method according to claim 1 , wherein the titre of the reference sample against the CAV is at least 12 (log 2 ) per 50 μl when examined against 300–1000 TCID 50 per 50 μl of the CAV.

4. The method according to claim 1 , further comprising the step of inactivating the CAV.

5. The method according to claim 1 wherein the CAV has the identifying characteristics of the CAV strain 319, which is deposited at the ECACC under accession no. V00012608.

6. The method according to claim 1 wherein the CAV is CAV strain 319, which is deposited at the ECACC under accession no. V00012608.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2006
From: AKZO NOBEL N.V.
To: INTERVET INTERNATIONAL B.V.
Reel/Frame 018490/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2006
From: SCHRIER, CARLA CHRISTINA; JAGT, HENRICUS JOHANNES MARIA
To: AKZO NOBEL N.V.
Reel/Frame 017704/0254 →
Priority Claims (1)
EP 00200719 · Feb 29, 2000 · regional
Continuity (2)
Division 0979387300 · Feb 27, 2001
Related Publication 20040157311A1 · Aug 12, 2004